Product Datasheet

Aurora A [p Thr288] Antibody - BSA Free
NBP3-05434

Unit Size: 100 ul

Store at -20C. Avoid freeze-thaw cycles.

www.novusbio.com technical@novusbio.com

Publications: 1

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NBP3-05434

Updated 4/13/2025 v.20.1



NBP3-05434

Aurora A [p Thr288] Antibody - BSA Free

Product Information	
Unit Size	100 ul
Concentration	Please see the vial label for concentration. If unlisted please contact technical services.
Storage	Store at -20C. Avoid freeze-thaw cycles.
Clonality	Polyclonal
Preservative	0.02% Sodium Azide
Isotype	IgG
Purity	Affinity purified
Buffer	PBS (pH 7.3), 50% glycerol
Target Molecular Weight	46 kDa

Product Description	
Host	Rabbit
Gene ID	6790
Gene Symbol	AURKA
Species	Human
Immunogen	A synthetic phosphorylated peptide around T288 of human Aurora A (NP_003591.2). RTTLC

Product Application Details	
Applications	Western Blot, Simple Western, ELISA
Recommended Dilutions	Western Blot 1:500-1:2000, Simple Western, ELISA

Images

Western Blot: Aurora A [p Thr288] Antibody [NBP3-05434] - Western blot analysis of extracts of HeLa and HT-29 cells, using Aurora A antibody (NBP3-05434) at 1:1000 dilution. HeLa cells were treated by Hydroxyurea (4mM) for 20 hours. Hela cells were treated by Nocodazole (50ng/mL) for 20 hours.HT-29 cells were treated by Hydroxyurea (4 mM) for 20 hours or treated by Nocodazole (100ng/mL) for 16 hours. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% BSA. Detection: ECL Basic Kit. Exposure time: 90s.	
Simple Western: Aurora A [p Thr288] Antibody - BSA Free [NBP3-05434] - Analysis of protein expression post-drug treatment. (A) CHLA-10 and (B) TC-71 cells treated with drugs were assessed for changes in protein expression 24 h post-treatment via capillary electrophoresis-based Wes analysis. Increased protein levels of KIF11, p-KIF11Thr926 AURKA, and p-AURKAThr288 were observed for the drug combination group, whereas KIF15 levels were noticeably lower. Similarly, enhanced cleaved-PARP expression was observed with the combination treatment. The uncropped blots are shown in Figures S8 and S9. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/37894278), licensed under a CC-BY license. Not internally tested by Novus Biologicals.	

Publications

Turaga SM, Vishwakarma V, Hembruff SL et al. Inducing Mitotic Catastrophe as a Therapeutic Approach to Improve Outcomes in Ewing Sarcoma Cancers 2023-10-10 [PMID: 37894278] (Simple Western, Human)

Novus Biologicals USA
10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada
21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd
19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information
www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NBP3-05434

HAF008	Goat anti-Rabbit IgG Secondary Antibody [HRP]
NB7160	Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]
NBP2-24891	Rabbit IgG Isotype Control
NBC1-28779	Recombinant Human Aurora A His Protein

Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP3-05434

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications